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Background: Neuroinflammatory responses have been recognized as an important aspect in the pathogenesis of
Parkinson’s disease (PD). Transcriptional regulation plays a critical role in the process of inflammation. Transcription
factor myocyte enhancer factor 2D (MEF2D) is identified as a central factor in transmission of extracellular signals
and activation of the genetic programs in response to a wide range of stimuli in several cell types, including
neurons. But its presence and function in microglia have not been reported. We therefore investigated the effect of
MEF2D in activated microglia on the progress of neuroinflammation and the survival of neurons.
Methods: BV2 cells and primary cultured glial cells were stimulated with lipopolysaccharide (LPS). Samples from
cells were examined for MEF2D expression, interleukin-10 (IL-10), and tumor necrosis factor alpha (TNF-α) by
immunoblotting, quantitative real-time PCR (qPCR) or enzyme-linked immunosorbent assay (ELISA). The activity
of MEF2D was examined by electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation assay
(ChIP). Recombinant lentivirus expressing shRNA specific to MEF2D was used to silence MEF2D expression in
BV2 cells. The role of IL-10 transcriptionally induced by MEF2D on neuronal survival was assessed by anti-IL-10
neutralizing antibody. The survival of neurons was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining.
Male C57bl/6 mice were used to establish an acute PD model. Brain sections and cell slides were tested by
immunofluorescence.
Results: We demonstrated that MEF2D was present in microglia. Activation of microglia was associated with an
increase in MEF2D level and activity in response to different stimuli in vivo and in vitro. MEF2D bound to a MEF2
consensus site in the promoter region of IL-10 gene and stimulated IL-10 transcription. Silencing MEF2D decreased
the level of IL-10, increased the TNF-α mRNA, and promoted inflammation-induced cytotoxicity, consistent with
the result of inhibiting IL-10 activity with an anti-IL-10 neutralizing antibody.
Conclusions: Our study identifies MEF2D as a critical regulator of IL-10 gene expression that negatively controls
microglia inflammation response and prevents inflammation-mediated cytotoxicity.
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Parkinson’s disease (PD) is the second most common neu-
rodegenerative disorder and characterized pathologically
by the loss of pigmented dopaminergic (DA) neurons in
the substantial nigra pars compacta (SNc) [1]. The precise
reasons for the selective loss of SNc DA neurons are not
entirely clear. Despite intensive researches on DA neurons,
recent studies show that glial cells, especially microglia, may
be involved in the progressive degeneration of DA neurons
[2-4]. Studies of post-mortem brain tissue of PD patients
show the presence of activated microglia in the affected brain
regions, strongly supporting that neuroinflammatory process
is associated with neuron loss [5]. Furthermore, the activated
microglia has been shown to contribute to DA neuronal
death not only by releasing pro-inflammation factors such as
tumor necrosis factor alpha (TNF-α) and interleukin-1 beta
(IL-1β) [6,7] but also by producing hyperoxides and peroxi-
dases including reactive oxygen species (ROS) and NADPH
oxidase [8-10].
As an important innate immunity in the central nervous
system (CNS), modest activated microglia is necessary
and beneficial for brain health. But controlling over vigor-
ous immune responses is critical for preventing this re-
activity from being over-activated and damaging the brain.
A lot of such controlling mechanisms may contribute to
the chronic pathogenesis in neurodegenerative diseases
[11,12]. Interleukin-10 (IL-10) is an anti-inflammation
cytokine with important roles in preventing inflammation
[13]. IL-10 regulates exuberant immune response of
microglia by inhibiting their release of pro-inflammatory
mediators such as TNF-α and IL-1β [14] and increasing
the release of anti-inflammatory mediators such as IL-1
receptor antagonist (IL-1ra) and soluble TNF-α receptors
[15,16]. Given the critical role of IL-10 in regulating the
course of microglia-mediated inflammatory response, elu-
cidating how IL-10 is regulated may provide valuable in-
formation for understanding the pathogenesis of PD. One
important aspect of controlling of IL-10 is the level of its
gene transcription. The structure of IL-10 gene promoter
contains AT-rich putative transcription factor myocyte en-
hancer factor 2 (MEF2) binding site. Recent evidence from
lymphocytes identifies IL-10 gene as a potential MEF2
transcriptional target [17,18].
MEF2s, initially identified as a nuclear factor import-
ant for muscle cell differentiation [19], have four mam-
malian isoforms, MEF2, A to D. The N-terminus of
MEF2 mediates dimerization and DNA binding, while
the C-terminus of MEF2 functions as transcriptional ac-
tivation domains. MEF2s have been found to play a cen-
tral role in the activation of the genetic programs that
regulate cell proliferation, differentiation, and apoptosis
in increasing types of cells [20]. Our previous study
demonstrates that MEF2D promotes the survival of DA
neurons in the SNc under stress conditions. Negativeregulation of MEF2D by toxic signals contributes to DA
neuronal death [21].
In spite of the studies of MEF2D in neurons, its func-
tion and regulation in microglia are entirely unknown.
In the present study, we examined the function of MEF2D
in activated microglia. Our data showed that the expression
and activity of MEF2D were significantly induced in acti-
vated microglia. MEF2D regulated the expression for IL-10
in microglia. Silencing MEF2D expression led to a decrease
in IL-10 mRNA and protein. This contributed to an in-
crease in inflammation-induced and microglia-mediated
toxicity to DA neuronal cells. These results establish a dir-
ect link between MEF2D and IL-10 activity in microglia-
mediated inflammatory response, suggesting that MEF2D
may play a critical role in preventing over-exuberant im-
mune responses and protecting neurons from microglia-
mediated neurotoxicity in PD.
Methods
Animal and tissue preparations
C57bl/6 male mice (25 ~ 30 g), purchased from the Ex-
perimental Animal Center of the Fourth Military Medical
University, were used according to the Guidelines for
Animal Care and Use of the Fourth Military Medical
University (Xi’an, People’s Republic of China). All efforts
were made to minimize animal suffering and to reduce
the number of animals used. Mice received four intraperi-
toneal (i.p.) injections of 20 mg/kg free base 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Sigma-Aldrich,
St. Louis, MO, USA) at 2-h intervals. Control mice were
injected with phosphate buffer solution (PBS) alone at the
same frequency. At 1 day, animals were anesthetized (10%
chloralhydrate, i.p.) and transcardially perfused with PBS.
The brains were fixed with cold 4% paraformaldehyde.
Serial brain sections (30 μm thick) containing the SNc
were collected for further analysis.
Cell culture and treatment
BV2 cells were cultured in Dulbecco’s modified Eagle’s
medium/F12 (DMEM/F12 containing 2.8 mM L-glutamine,
15 mM HEPES) (Gibco, Grand Island, NY, USA) supple-
mented with 5% fetal bovine serum (FBS) (Gibco), and
incubated with 5% CO2 at 37°C.
Primary mixed glial cell cultures were derived from
post-natal days 0 to 3 (P0-P3) Sprague-Dawley rat brains.
Shortly, the whole brains were dissociated in trypsin with-
out EDTA for 10 min at 37°C and then were cultured in
DMEM/F12 supplemented with 10% FBS. Mixed glial cell
cultures, which were cultured in poly-D-lysine-coated (0.1
mg/ml) (Sigma-Aldrich) T75 flasks and on cell slides,
were incubated at 37°C and 5% CO2 for 13 to 16 days.
When the cells in T75 flasks became confluent, the flasks
were shaken at 250 rpm/min for 2 h to detach microglia.
The microglia after purification were cultured in DMEM/
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lowing experiments.
SN4741, a mouse embryonic substantial nigra-derived
cell line [22], was cultured at 33°C with 5% CO2 in RF
medium (DMEM with 10% FBS, 1% D-glucose, 1%
penicillin-streptomycin, and 140 mM L-glutamine). Ex-
periments were usually done when cells reached 50% to
60% confluence.
When reaching 60% to 70% confluence, the BV2 cells
and primary microglia cells were exposed to lipopolysac-
charide (LPS, 1.0 μg/ml) (Sigma-Aldrich) for a designed
time point, respectively. Then, the cells were enriched
for the following experiments.
For neutralizing antibody experiments, BV2 cells were
treated with 1.0 μg/ml LPS in the presence or absence
of anti-IL-10 neutralizing antibody (1.0 μg/ml, Abcam,
Cambridge, UK) for 24 h.
Lentivirus infection
Recombinant lentivirus vector expressing shRNA-MEF2D
to silence MEF2D gene expression was obtained commer-
cially from Hanbio, Shanghai, China. BV2 cells were
seeded in a six-well plate and were infected with lentivirus
in 1 ml medium for 4 h. The medium was added to 2 ml,
and cells were continuously infected for another 24 h.
After being replaced with fresh medium, the cells were
cultured and used for studies.
Immunofluorescence
Mixed glia cell slides and brain sections were fixed with
4% formaldehyde solution, incubated with 0.1% Triton
X-100 for 30 min, and blocked with 5% bovine serum
albumin (BSA) (Sigma-Aldrich) in PBS for 30 min. Sam-
ples were incubated at 4°C overnight with primary anti-
Iba-1 (1:50; Abcam, Cambridge, UK) combined with
anti-MEF2D (1:200; BD Transduction Laboratories, San
Jose, CA, USA); then they were washed three times with
PBS and incubated with secondary antibody conjugated
with FITC in room temperature for 2 h. Samples were
counterstained with DAPI (1:500; Sigma) for 10 min
and photographed using a confocal microscope (C2 Si,
Nikon, Minato, Japan).
Immunoblotting
Cell protein was harvested with ice-cold lysis buffer con-
taining protease inhibitors. Protein was separated by so-
dium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE), and then the separated protein was trans-
ferred onto polyvinylidene fluoride (PVDF) membranes
(Millipore Corporation, Bedford, MA, USA). After 2-h
blocking with 5% fat-extracted milk at room temperature,
the membranes were incubated overnight at 4°C with pri-
mary antibodies against MEF2D (1:3,000; BD) and β-actin
(1:4,000; Abcam). Then the membranes were washed withTBST three times and then were treated with horseradish
peroxidase-conjugated secondary antibody for 2 h at room
temperature. Protein bands were visualized by chemilu-
minescence detection.
Quantitative real-time PCR
Total RNA was extracted from each sample according
to the manufacturer’s protocol for TRIzol reagent (Invi-
trogen, Paisley, Scotland, UK). Complementary DNA
(cDNA) was generated from total RNA using random
primer and MMLV reverse transcriptase (Invitrogen),
using a final volume of 20 μl. Quantitative real-time PCR
(qPCR) analysis was performed in triplicate using Quanti-
Fast™ SYBR® Green PCR Kit (Qiagen, Hilden, Germany).
All gene-specific mRNA expression values were compared
to β-actin mRNA levels as a standard. The primer se-










Chromatin immunoprecipitation assay (ChIP) was done
following a procedure provided by a ChIP Assay Kit
(Millipore). The product of DNA was analyzed by using
qPCR and semiquantitative PCR with IL-10 gene pro-
moter specific primers as follows:
forward, 5′-CTGTCTGCCTCAGGAAAT-3′;
reverse, 5′-CTAAAGAACTGGTCGGAAT-3′.
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) was per-
formed as described [23]. The Binding reactions were
incubated with MEF2 specific probe or mutant probe,
and for super shift assay, reactions were incubated with
MEF2D antibody for 1 h at 4°C after incubation with
labeled probe. The sequences of the probes used for
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Detection of IL-10 in the supernatant of treated and un-
treated BV2 cells cultures was determined with a mouse
IL-10 enzyme-linked immunosorbent assay (ELISA) kit
(R&D Systems, Wiesbaden, Germany) according to manu-
facturer procedures, and results were raised as picogram
per milliliter.
MTT assay
Cells were seeded in 96-well plates (5 × 103 cells/well) and
incubated at 37°C. After treatment, 20 μl of 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (5
mg/ml) (Millipore) were added to each well, and the plate
was incubated for 4 h. Then, after removing supernatant,
150 μl of dimethylsulfoxide (DMSO) (Millipore) was
added to each well and mixed thoroughly for 10 min.
The optical density (OD) was measured at 490 nm.
TUNEL staining
For terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) staining, FragEL™ DNA Frag-
mentation Detection Kit (Millipore) was used according
to manufacturer’s instructions.
Statistical analyses
Data were expressed as mean ± standard error of the mean
(SEM) from at least three independent experiments. Data
were analyzed by either one-way ANOVA or two-way
ANOVA as appropriate. Statistical analyses were carried
out using SPSS 19.0. A value of P < 0.05 was considered
statistically significant.
Results
Induction of MEF2D expression during microglia activation
Previous studies show that MEF2s participate in the
regulation of immune responses in T and B lymphocytes
[24,25]. That prompted us to test whether MEF2D might
be involved in inflammatory response in the processes of
PD. For this, we used neurotoxin MPTP-induced loss of
SNc DA neurons, a widely used model of PD. After 24 h
of MPTP administration, we examined the effects of this
toxin on tyrosine hydroxylase (TH)-positive DA neurons
in SNc. The acute MPTP exposure clearly caused a loss
of immunohistochemical signal for TH in SNc. We stained
the same brain sections for Iba-1, a marker for activated
microglia, and found that MPTP induced a significant
increase in Iba-1 signal (Figure 1A). We then stained the
brain section with a monoclonal anti-MEF2D antibody.
This antibody recognizes MEF2D as a single band by im-
munoblotting and has been used successfully in immuno-
staining of brain tissues [26]. Immunofluorescence analysis
showed that MEF2D expression was clearly increased in
thick bundles around swollen somata microglia in SNc re-
gion after MPTP injection. Moreover, the high levels ofMEF2D expression were colocalized with Iba-1 (Figure 1B).
These data demonstrate that MEF2D level increases with
the activation of microglia in MPTP-PD animal model.
Induction of expression and activity of MEF2D in BV2 cells
To further confirm MEF2D expression and investigate
its role in microglia, we performed experiments in BV2
cells, a mouse microglia cell line. We first tested MEF2D
mRNA expression by qPCR under basal condition. There
was a low but detectable MEF2D mRNA in BV2 cells. The
level of MEF2D transcript was gradually increased follow-
ing LPS treatment, reaching a significantly higher level at
18 and 24 h after LPS treatment (Figure 2A). In correl-
ation with the change of MEF2D mRNA, the level of
MEF2D protein was also increased gradually following
LPS treatment. The level of MEF2D protein gradually in-
creased 12 h after LPS exposure and reached a much
higher level 24 h post-treatment (Figure 2B). To examine
this fact in different cell models, we cultured mixed glial
cells or purified primary microglia and treated the cells
with LPS. Our analysis showed that LPS treatment signifi-
cantly increased the levels of MEF2D in both mixed glial
and primary microglia cells by immunofluorescence or
immunoblotting, respectively (Additional file 1: Figure
S1A and B). To determine if the change in MEF2D level
correlates with its activity, we performed EMSA to assess
MEF2D DNA binding capacity. The whole cell extract
was prepared from BV2 cells after 24 h of LPS treatment
and examined for the binding to labeled DNA probe
containing MEF2 binding consensus site. Control lysate
showed a detectable formation of protein and probe
complex (Figure 2C). Mutation of the MEF2 binding site
in the DNA nearly abolished the formation of the com-
plex. Addition of anti-MEF2D to the reaction super shifted
the formation of the complex, indicating that MEF2D was
a major protein component in the complex (Figure 2C).
This formation of MEF2D and probe complex was signifi-
cantly inducted in lysates after LPS treatment, suggesting
that increased MEF2D activity accompanies LPS-induced
activation of BV2 cells.
Identification of MEF2D target DNA in microglia
Our above data showed that MEF2D expression was
induced by LPS relatively late, suggesting that MEF2D
may function in activated microglia rather than in the
early activating stage. To test this, we performed time
course studies to establish the pattern of MEF2D protein
following LPS treatment (Figure 3A, top graph) and then
assessed the mRNA levels of pro-inflammatory factor
TNF-α and anti-inflammatory factor IL-10 following LPS.
Our data showed that the level of TNF-α mRNA was in-
duced early and reached its peak 2 h after LPS (Figure 3A,
middle graph). In contrast, the level of IL-10 mRNA was
induced more gradually and showed significant increase at
Figure 1 Induction of MEF2D expression in the activated microglia. (A) Loss of TH signals in MPTP-treated mouse brain. SNc brain sections
from mice injected with MPTP were stained with the antibodies indicated by immunofluorescence (TH, green; Iba-1, red; bar = 200 μm; and
n = 3). (B) Expression of MEF2D in activated microglia (MEF2D, green; Iba-1, red; bar = 100 μm; and n = 3).
Figure 2 LPS-induced increase in expression and activity of MEF2D in BV2 cells. (A) LPS-induced increase in MEF2D mRNA expression in
BV2 cells. BV2 cells were exposed to 1.0 μg/ml LPS for 6, 12, 18, or 24 h, and the mRNA levels of MEF2D were quantified by qPCR and normalized
to β-actin mRNA level as described in ‘Methods’. Data from three independent experiments were expressed as the mean ± SEM and analyzed by
one-way ANOVA (**P < 0.01). (B) LPS-induced increase in MEF2D protein in BV2 cells. BV2 cells were treated for the indicated time as described
above and immunoblotted for MEF2D. (B bottom graph) Relative quantification of MEF2D. Data were expressed as mean ± SEM from at least
three independent experiments and analyzed by one-way ANOVA (**P < 0.01). (C) LPS-induced increase in MEF2D activity. The whole cell
extracts were prepared from BV2 cells treated with or without LPS for stimulating 24 h and analyzed by EMSA. Arrow indicates the position of
MEF2D-probe complex (unlabelled probe: a 100-fold excess of unlabelled probe was added in the reaction; MT probe: probe with MEF2 binding
site mutated).
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Figure 3 Regulation of IL-10 gene expression by MEF2D. (A) LPS-induced time-dependent changes of MEF2D protein and cytokines in BV2
cells. BV2 cells treated with LPS as described in Figure 2A were analyzed by immunoblotting for MEF2D and by qPCR for TNF-α and IL-10 mRNA
levels. Data from three independent experiments were expressed as the mean ± SEM and analyzed by one-way ANOVA (*P < 0.05; **P < 0.01).
(B) Identification of a conserved MEF2 binding site in the IL-10 gene promoter of different species. The underlined sequence indicates the MEF2
binding site. Black-shaded areas show the conversed MEF2 binding site in the IL-10 gene promoter of different species. (C, D) Binding of MEF2D
to the IL-10 gene promoter region containing the conserved site in BV2 cells. BV2 cells treated with or without LPS for 24 h were analyzed by
ChIP. The result was showed by standard endpoint PCR (C) and qPCR (D). Data from three independent experiments were expressed as the
mean ± SEM and analyzed by one-way ANOVA (*P < 0.05; **P < 0.01).
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the pattern of IL-10 mRNA response matched well with
that of MEF2D protein and prompted us to search for
possible MEF2 regulatory target in IL-10 gene promoter.
Analyzing IL-10 gene promoter sequence reveals the pres-
ence of a putative MEF2 binding site (5′-CC[A/t][t/a]
AAATAG-3′) [27], which was conserved among several
species examined (Figure 3B). To test whether MEF2D
binds to this putative MEF2 site in IL-10 gene, we car-
ried out ChIP assay. Our ChIP analysis showed that
MEF2D bound specifically to a region within IL-10 gene
promoter that contains the putative site in BV2 cells by
either end product PCR (Figure 3C) or qPCR (Figure 3D).
This binding was significantly induced in response to
LPS treatment.
Transcriptional regulation of IL-10 gene by MEF2D
To assess the role of MEF2D in IL-10 gene transcription,
we infected BV2 cells with recombinant lentivirus express-
ing shRNA specific to MEF2D (sh-MEF2D). Immunoblot-
ting analysis showed that this approach effectively reducedLPS-induced increase in the level of MEF2D protein
(Figure 4A). To test the effect of silencing MEF2D ex-
pression, we first analyzed the IL-10 mRNA level with
qPCR after LPS treatment. The results showed that
silencing MEF2D expression significantly reduced the
level of IL-10 transcript in response to LPS (Figure 4B).
Similarly, reducing MEF2D level also significantly atten-
uated the LPS-induced increase of IL-10 cytokine in
culture media determined by ELISA (Figure 4C). As an
anti-inflammatory cytokine, IL-10 plays a critical role in
preventing inflammatory and autoimmune pathologies.
One of protective mechanisms of IL-10 is through inhi-
biting the production of the proinflammatory cytokines
such as TNF-α. Analysis of TNF-α mRNA by qPCR
showed that silencing MEF2D also led to a significant
increase in its level 24 h after LPS treatment (Figure 4D,
top graph). In contrast, silencing MEF2D had little
effect on TNF-α mRNA level at either 2 or 6 h of LPS
treatment (Figure 4D, bottom graph). Together, these
data suggest that MEF2D is required for IL-10 gene tran-
scription in the activated microglia. Silencing MEF2D-
Figure 4 Effect of knocking-down MEF2D on IL-10 expression. (A) BV2 cells were infected with recombinant lentivirus expressing either
control shRNA or shRNA to MEF2D (sh-MEF2D) and then treated with LPS for 24 h. The effectiveness of sh-RNA MEF2D was examined by
immunoblotting. (A bottom graph) Relative quantification of MEF2D. Data from three independent experiments were expressed as the mean ±
SEM and analyzed by one-way ANOVA (**P < 0.01). (B) The effect of sh-MEF2D on IL-10 mRNA in BV2 cells. BV2 cells infected with sh-MEF2D
lentivirus were treated with LPS and analyzed for IL-10 mRNA by qPCR. Data from three independent experiments were expressed as the mean ±
SEM and analyzed by two-way ANOVA (**P < 0.01). (C) The effect of sh-MEF2D on the level of secreted IL-10. Culture media from BV2 cells treated
as descried under (B) were harvested for ELISA. Data from three independent experiments were expressed as the mean ± SEM and analyzed by
two-way ANOVA (**P < 0.01). (D) The effect of sh-MEF2D on TNF-α mRNA in BV2 cells. BV2 cells treated as described under (B) and exposed to
LPS for different times were analyzed for TNF-α mRNA by qPCR. Data from three independent experiments were expressed as the mean ± SEM
and analyzed by two-way ANOVA (**P < 0.01).
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ing late stage in response to LPS.
The protective effect of MEF2D-IL-10 on the death of TH+
neuronal cells
To test the effect of MEF2D-IL-10 on the survival of
neurons, we designed a media transfer assay. For this
experiment, we treated BV2 cells with LPS for 12 h,
changed media, continued LPS treatment for another 12
h, collected conditioned media (CM), transferred CM to
cultured DA neuronal line SN4741 cells, and measured
neurotoxicity by MTT assay (Figure 5A). This analysis
showed that CM collected from BV2 cells at the second
12 h was less toxic to SN4741 cells. Importantly, silen-
cing MEF2D greatly enhanced the cytotoxicity of CM
compared to control (Figure 5B). To confirm the effect
of MEF2D-IL-10 on cellular survival and death, we co-treated cells with LPS and anti-IL-10 neutralizing anti-
body. Consistent with the effect of shRNA-MEF2D,
blocking IL-10 clearly reduced the survival of SN4741
cells exposed to post-12 h CM by MTTassay (Figure 5C).
TUNEL assay showed that pre-12 h CM caused a signifi-
cant increase in the number of TUNEL-positive cells
than post-12 h CM (Figure 5D, left panel). Silencing
MEF2D expression and neutralizing IL-10 both signifi-
cantly increased the toxicity of post-12 h CM (Figure 5D,
middle panel). Thus, decreasing MEF2D alters the pro-
file of cytokine and prolongs the cytotoxic effect of LPS.
Discussion
Transcription factor MEF2s play important roles in neur-
onal development, synaptic plasticity, and survival [28-30].
Our previous studies show regulation of MEF2D activity by
autophagy pathway is related to DA neuronal homeostasis
Figure 5 The effect of knocking-down MEF2D on microglia-mediated cytotoxicity. (A) Experiment paradigm for the collection of
conditioned media (CM). Media collected from BV2 cells treated with LPS for 12 h were labeled as pre-12 h CM. After the first 12 h, cells were
washed and placed in fresh media for another 12 h (post-12 h CM). CM was then added to SN4741 cells for 48 h. (B) The effect of silencing
MEF2D on CM-mediated toxicity. CM was collected from BV2 cells infected with either control (sh-Control) or sh-MEF2D lentivirus (sh-MEF2D).
The viability of SN4741 cells was determined by MTT. Data from three independent experiments were expressed as the mean ± SEM and analyzed
by two-way ANOVA (**P < 0.01). (C) The effect of neutralizing IL-10 on CM-mediated toxicity. CM was collected from BV2 cells with (anti-IL-10+)
or without (anti-IL-10−) anti-IL-10 neutralizing antibody. The viability of SN4741 cells was determined by MTT. Data from three independent
experiments were expressed as the mean ± SEM and analyzed by two-way ANOVA (**P < 0.01). (D) The effect of silencing MEF2D or neutralizing
IL-10 on CM-induced toxicity. For (D) left panel, the effect of CM from BV2 cells treated with LPS on SN4741 viability was assessed by TUNEL
staining. For (D) middle panel, the effect of post-12 h CM collected from BV2 cells treated as in (B) or (C) were assessed by TUNEL assay in
SN4741 cells. For (D) right panel, the quantification of the percentages of TUNEL-positive population. Data from three independent experiments
were expressed as the mean ± SEM and analyzed by one-way ANOVA (**P < 0.01).
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few studies have reported a link between MEF2s and im-
mune system. For example, MEF2s have been found to
participate in immune responses of T and B lymphocytes.
In addition, MEF2C level is found to increase in the acti-
vated microglia around the hippocampus after ischemia
[31-33]. In the current study, we provide the first evidence
demonstrating the presence of MEF2D in microglia and
its function in microglia-mediated inflammation response.
Our data indicate that in quiescent microglia, the levels of
both MEF2D mRNA and protein are low. Stimulation
by neurotoxin or LPS significantly induces MEF2D level
and activity. Further, we demonstrate that the increase
in MEF2D level is necessary for the transcriptional
activation of IL-10 gene expression and for damping the
level of pro-inflammatory cytokines such as TNF-α. Thus,
our data establish MEF2D as a critical negative regulator
of neuroinflammation.Our previous findings indicate that MEF2D functions
in the nucleus and mitochondria in SNc DA neurons to
promote neuronal survival [23,27]. Our current data have
revealed that MEF2D-mediated regulation of IL-10 in
microglia protects a cell line derived from DA neuronal
progenitor against the cytotoxicity exerted by prolonged
activation of microglia. Together, they indicate control of
the over-activation of microglia as a novel mechanism
by which MEF2D protects cells from inflammation-
induced toxicity. It is important to investigate the tem-
poral change of MEF2D in microglia in PD and determine
if loss of MEF2D function in microglia may contribute
inflammation-related injury in the pathogenic process of
the disease.
Our data indicate that MEF2D mRNA level is robustly
induced in microglia in response to LPS. The precise
mechanisms underlying this induction remain unknown. It
may involve either activation of mef2d gene transcription
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MEF2D transcript has been reported during hepatic
stellate cells activation, a stimulation analogous to LPS-
induced microglial response [34]. Since it is currently
unclear how mef2d gene promoter is regulated, further
studies are needed to clarify the regulatory mechanism
(s) involved.
As an anti-inflammatory cytokine, IL-10 plays a critical
role in controlling the intensity of inflammatory response
by inhibiting production of various pro-inflammatory cy-
tokines such as IL-1, IL-6, and TNF-α [35,36]. Expression
of IL-10 gene is highly inducible, which represents a major
mechanism of regulation. Several transcription factors
have been implicated in IL-10 regulation including C/
EBPβ, SP1, NF-κB, and CREB under various conditions
[37-40]. But how IL-10 expression is regulated in micro-
glia has not been elucidated. Our data show that the
kinetics of MEF2D expression and activity parallels closely
with the induction of IL-10. MEF2D binds directly to a
region in IL-10 gene promoter that contains a well-
conserved MEF2D binding site. Moreover, MEF2D activity
is required for LPS-induced IL-10 mRNA expression. To-
gether, our findings provide strong evidence supporting
MEF2D as a primary transcription factor that directly reg-
ulates IL-10 gene transcription in microglia.
Conclusions
Our findings extend the cellular roles of MEF2D from
neurons to microglia and further expand the mecha-
nisms by which MEF2D regulates neuronal survival.
Since communication between microglia and neurons
has been increasingly being recognized to be important
for various neuronal processes, our findings raise the
question of whether MEF2D may play other roles in
addition to regulation of inflammation in microglia and
therefore is intricately involved in modulating microglia-
neuron homeostasis. Overall, the beneficial role played
by MEF2D in modulating microglia immune response
supports the targeting MEF2D as a therapeutic strategy for
reducing unwanted neuroinflammation.
Additional file
Additional file 1: Figure S1. Induction of MEF2D expression by LPS in
mixed glial cells and purified primary microglia. (A) Mixed glial cells from
rat were treated with 1.0 μg/ml LPS for the indicated time and analyzed
by immunofluorescence (bar = 25 μm). (B) Purified primary microglia was
analyzed by immunoblotting. Bottom graph shows the quantification of
MEF2D. Data from three independent experiments were expressed as
mean ± SEM and analyzed by one-way ANOVA (**P < 0.01).
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